Determination of Lipids Levels among Patients with Chronic Lymphocytic Leukemia in Kurdistan Region of Iraq
Keywords:
Chronic Lymphocytic Leukemia (CLL), Dyslipidemia, Hypocholesterolemia, Blood lipid profilesAbstract
Objective: Hypocholesterolemia is a metabolic disorder that can occur in malignancies. Distinct dyslipidemia profiles have been demonstrated in adult and pediatric hematologic malignancies. The aim of this study to assess the lipid profile of patients diagnosed with chronic lymphocytic leukemia. Methods: We assessed lipid profile of Fifty-one patients with chronic lymphocytic leukemia were attended two hematology laboratory facilities of hospital in Erbil and Duhok governorates. Wherever, total cholesterol, triglyceride (TG) values, Low Density Lipoprotein (LDL) and High Density Lipoprotein (HDL) were analyzed. For statistical analysis, the student’s t-test and the One-way ANOVA test were utilized. In order to do the statistical analysis, SPSS version 26 was used. 95% confidence intervals and a significance threshold of p 0.05 were used to analyze the results. Results: Total cholesterol, LDL and HDL levels were significantly lower in the study group in conjunction with the progression of the disease stages (p<0.01). Conclusion: Hypocholesterolemia and low LDL and HDL levels can occur in chronic lymphocytic leukemia. It should be borne in mind that malignancies may be the etiology of unexpected hypocholesterolemia and hypertriglyceridemia. The impact of dyslipidemia on the pathogenesis and prognosis of chronic lymphocytic leukemia requires further study.
Downloads
References
Dores GM, Anderson WF, Curtis RE, Landgren
O, Ostroumova E, Bluhm EC, et al. Chronic
lymphocytic leukaemia and small
lymphocytic lymphoma: overview of the
descriptive epidemiology. British journal of
haematology. 2007;139(5):809–19.
Treatment of Chronic Lymphocytic Leukemia
| NEJM [Internet]. [cited 2022 Oct 3].
Available from:
https://www.nejm.org/doi/full/10.1056/N
EJMra1908213
Carbone A, Gloghini A. In situ follicular
neoplasia. Atlas of Genetics and Cytogenetics
in Oncology and Haematology. 2017
Mayengbam SS, Singh A, Pillai AD, Bhat
MK. Influence of cholesterol on cancer
progression and therapy. Translational
Oncology. 2021 Jun 1;14(6):101043.Quesney-Huneeus V, Galick HA, Siperstein
MD, Erickson SK, Spencer TA, Nelson
JA. The dual role of mevalonate in the cell
cycle. Journal of Biological Chemistry.
;258(1):378–85.
Fiorenza AM, Branchi A, Sommariva D.
Serum lipoprotein profile in patients with
cancer. A comparison with non-cancer
subjects. International Journal of Clinical
and Laboratory Research.
;30(3):141–5.
Kuliszkiewicz-Janus M, Malecki R,
Mohamed A. Lipid changes occuring in
the course of hematological cancers.
Cellular and Molecular Biology Letters.
;13(3):465–74.
Tomiki Y, Suda S, Tanaka M, Okuzawa A,
Matsuda M, Ishibiki Y, et al. Reduced lowdensity-lipoprotein cholesterol causing low
serum cholesterol levels in gastrointestinal
cancer. A case control study. Journal of
Experimental and Clinical Cancer Research.
; 23: 233–40.
Dessì S, Batetta B, Pani A, Spano O, Sanna
F, Putzolu M, et al. Role of cholesterol
synthesis and esterification in the growth
of CEM and MOLT4 lymphoblastic cells.
Biochemical Journal. 1997;321(3):603–8.
Baroni S, Scribano D, Zuppi C, Pagano L,
Leone G, Giardina B. Prognostic
relevance of lipoprotein cholesterol levels
in acute lymphocytic and nonlymphocytic
leukemia. Acta haematologica.
;96(1):24–8.
Friedewald WT, Levy RI, Fredrickson DS.
Estimation of the Concentration of LowDensity Lipoprotein Cholesterol in
Plasma, Without Use of the Preparative
Ultracentrifuge. Clinical Chemistry. 1972
Jun 1;18(6):499–502.
Santos CR, Schulze A. Lipid metabolism in
cancer. The FEBS Journal.
;279(15):2610–23.
Mulas MF, Abete C, Pulisci D, Pani A,
Massidda B, Dessì S, et al. Cholesterol
esters as growth regulators of lymphocytic
leukaemia cells. Cell proliferation.
;44(4):360–71.
Hegele RA. Plasma lipoproteins: genetic
influences and clinical implications.
Nature Reviews Genetics.
;10(2):109–21.
Lorenc J, Kozak-Michalowska I, PolkowskaKulesza E. Disorders of lipid and lipoprotein
metabolism in patients with chronic
lymphocytic leukemia. I. Preliminary
evaluation of lipemia and HDL fractions in
various stages of the disease. Przeglad
Lekarski. 1989;46(10):713–8.
Shor R, Wainstein J, Oz D, Boaz M, Matas Z, Fux
A, et al. Low serum LDL cholesterol levels and
the risk of fever, sepsis, and malignancy. Annals
of Clinical & Laboratory Science.
;37(4):343–8.
Ahn J, Lim U, Weinstein SJ, Schatzkin A,
Hayes RB, Virtamo J, et al. Prediagnostic
total and high-density lipoprotein
cholesterol and risk of cancer. Cancer
epidemiology, biomarkers & prevention.
;18(11):2814–21.
Anchisi C, Batetta B, Sanna F, Fadda AM,
Maccioni AM, Dessi S. HDL subfractions
as altered in cancer patients. Journal of
pharmaceutical and biomedical analysis.
;13(1):65–71.
Gonçalves RP, Rodrigues DG, Maranhão RC.
Uptake of high density lipoprotein (HDL)
cholesteryl esters by human acute
leukemia cells. Leukemia research.
;29(8):955–9.
Krieger M. Charting the fate of the" good
cholesterol": identification and characterization
of the high-density lipoprotein receptor SR-BI.
Annual review of biochemistry. 1999; 68: 523.
Sakashita AM, Bydlowski SP, Chamone DAF,
Maranhao RC. Plasma kinetics of an artificial
emulsion resembling chylomicrons in patients
with chronic lymphocytic leukemia. Annals of
hematology. 2000;79(12):687–90.
Sherwin RW, Wentworth DN, Cutler JA, Hulley
SB, Kuller LH, Stamler J. Serum cholesterol
levels and cancer mortality in 361662 men
screened for the multiple risk factor
intervention trial. Jama. 1987;257(7):943–8.
Yavasoglu I, Sargin G, Yilmaz F, Altındag S,
Akgun G, Tombak A, et al. Cholesterol
levels in patients with chronic lymphocytic
leukemia. Journal of the National Medical
Association. 2017;109(1):23–7.
Onat A, Sansoy V, Dönmez K, Keleş İ, Ökçün B,
Kahraman G, et al. Investigations stable blood
cholesterol but rising triglyceride levels in
Turkish adults. Archives of the Turkish Society
of Cardiology. 1996;24(7):392–8.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
